FORM 4

obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>HILZINGER KURT J</u>						2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK]										all applicable) Director		ng Pers	g Person(s) to Issuer 10% Owner	
	`	HERAPEUTICS,	Middle) INC.		3. Date of Earliest Transaction (Month/Day/Yea 12/21/2018											belov	cer (give title w)		Other (specify below)	
(Street) CRANBI (City))8512 Zip)		- 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									i. Indivi ine) X	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tabl	e I - No	n-Deriv	/ative	Se	curitie	es Acc	quired,	Dis	posed o	f, or	Bene	efici	ally (Owne	ed			
Da				Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)				ties Acquired (A) d Of (D) (Instr. 3, 4				5. Amount of Securities Beneficially Owned Following Reported		Form:	nership Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(4	A) or D)	Price	Trans		action(s) 3 and 4)			(111501.4)
Common Stock 1					1/2018				P		3,600		Α	\$0.65(1)		41,400(2)			D	
Common	ommon Stock 12/					4/2018					1,113	3	Α	\$0.66(3)		(3) 42,513			D	
		Та									osed of, onvertib					vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	n Date,	Date, Transa Code		ı of li		Expiration	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			ivative urity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D or Indirec (I) (Instr.	vnership rm: rect (D) Indirect	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nun of	ount nber res						

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.63 \$0.6706, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
- 2. Includes an aggregate of 7,246 shares that were issued upon vesting and settlement of Restricted Stock Units previously reported in a Form 3 filed with the Securities and Exchange Commission on May 12, 2016 but erroneously omitted from Column 5 in subsequent filings.
- 3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.65 \$0.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

/s/ Lawrence A. Kenyon, Attorney-in-Fact

12/26/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.